查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1970996

沙眼治療市場－全球產業規模、佔有率、趨勢、機會、預測：按給藥途徑、藥物類別、地區和競爭格局分類，2021-2031年

Trachoma Treatment Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Route of Administration (Oral, and Topical), By Drug Class (Macrolides, Tetracycline, Ophthalmic Anti-infective), By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 181 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球沙眼治療市場預計將從 2025 年的 6.574 億美元成長到 2031 年的 10.2995 億美元，複合年成長率為 7.77%。

該市場專注於提供治療性介入和外科手術，主要使用阿奇黴素等抗生素治療披衣菌感染衣原體感染疾病和矯正瞼內翻（睫毛向內翻轉）。該行業的主要驅動力是協調實施SAFE策略和強力的國際藥品捐贈計劃，這些計劃能夠實現大規模用藥。事實上，根據國際沙眼預防聯盟（ICTC）的數據，到2024年，將有4,440萬人接受沙眼抗生素治療。

市場概覽
預測期 2027-2031
市場規模：2025年 6.574億美元
市場規模：2031年 1,029,950,000 美元
複合年成長率：2026-2031年 7.77%
成長最快的細分市場 口服
最大的市場 北美洲

然而，限制市場擴張的一大障礙是向偏遠和受衝突影響地區分發治療藥物的物流複雜性。在這些高發地區，基礎設施不足和當地局勢動盪經常擾亂醫療供應鏈，阻礙外科手術團隊的部署，並有效地延緩了徹底根除疾病的努力。

市場促進因素

隨著各國加速實現2030年根除沙眼目標的步伐，世衛組織SAFE策略的協調實施在市場拓展中發揮關鍵促進者。這個綜合框架結合了手術、抗生素、臉部衛生和環境改善，要求在流行地區進行廣泛的干涉措施，並刺激對外科耗材和治療性抗生素的需求。同時，各國政府正優先進行嚴格的檢測，以確認持續的低盛行率，從而推動檢驗工作。這些協調努力的成效顯而易見，世衛組織2024年10月發布的《沙眼概況介紹》確認，已有20個國家被認定為已根除沙眼這一公共衛生問題。

策略性的企業藥品捐贈和國際非政府組織的持續資助，透過確保阿奇黴素和營運資源的穩定供應，進一步維護了市場穩定。在政府預算不足的低收入地區，公私夥伴關係對於維持大規模藥物管理計畫至關重要，能夠有效彌合臨床需求與商業性供應之間的差距。輝瑞公司於2024年3月發布的《2023年影響報告》充分體現了這種支持的規模，該報告詳細介紹了公司向國際沙眼預防組織（ITI）捐贈其第10億劑希舒美（Zithromax）的情況。考慮到世界衛生組織（WHO）報告稱，到2024年，仍有約1.03億人居住在需要沙眼預防的地區，這項捐贈意義重大。

市場挑戰

將治療藥物運送到偏遠和受衝突影響地區的物流挑戰，直接限制了全球沙眼治療市場的成長，因為這切斷了供應與患者需求之間的關鍵連結。由於該市場從根本上依賴大規模藥物管理（MDA）宣傳活動和流動手術營，一旦實際通道中斷，服務提供就會立即停止。此外，不穩定地區的基礎設施不足和安全問題也阻礙了醫護人員和抗生素的部署。這些障礙有效地縮小了市場規模，導致現有治療資源無法在最迫切需要的地區得到利用。

因此，這種運作瓶頸導致大量高風險族群無法得到治療，儘管有捐贈藥品，但防治工作仍停滯不前。這種可近性問題的嚴重性使得市場無法彌合潛在需求與實際供應之間的差距，情況十分嚴峻。世界衛生組織（世衛組織）的研究顯示，截至2025年4月，約有1.026億人居住在沙眼流行地區，需要接受介入治療。這項數據表明，市場很大一部分仍然面臨物流上的障礙，阻礙了根除策略的全面實施。

市場趨勢

智慧型手機數位診斷工具的普及應用正在從根本上改變全球沙眼治療市場，使活躍性行為感染叢集的識別和追蹤更加現代化。由於傳統的紙本調查在即時決策方面效率低下，相關人員正在整合行動醫療應用程式，利用演算法嚴重程度評估和GPS定位技術，實現高精度的流行率地圖繪製。這使得抗生素治療方法能夠迅速部署到疫情熱點地區。 Sightsavers於2025年7月發布的2024會計年度年度報告詳細記錄了這項營運現代化的規模，其中包括990萬次眼科檢查。該數位平台透過簡化偏遠地區的患者追蹤和報告流程，正在擴大服務範圍。

同時，隨著越來越多的國家將活躍感染病例降至公共衛生關注閾值以下，市場正向經過檢驗的監測策略轉型。這一趨勢正推動大規模藥物管理（MDA）宣傳活動向有針對性的監測通訊協定轉變，以便檢測并快速應對疾病復發，對專業診斷培訓和永續監測框架的需求遠高於大規模抗生素採購。為了凸顯這項轉變的迫切性，國際抗擊沙眼聯盟（ICTC）於2025年4月發布的《2025年差距分析報告》指出，又有五個國家實現了其根除沙眼的盛行率目標。這表明市場正發生重大轉變，需要為穩健的、經過檢驗的監測系統提供資金籌措並進行開發，以鞏固這些成果。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球沙眼治療市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 給藥途徑（口服、局部）
    • 藥物分類（大環內酯類、四環黴素、眼用抗感染藥）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美沙眼治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲沙眼治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區沙眼治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲沙眼治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲沙眼治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球沙眼治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Novartis AG
  • Gilead Sciences Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • BioCryst Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Boehringer Ingelheim GmBH
  • Pfizer, Inc.
  • Sanofi AG
  • Janssen Pharmaceutical, Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 23821

The Global Trachoma Treatment Market is projected to expand from USD 657.40 Million in 2025 to USD 1029.95 Million by 2031, reflecting a compound annual growth rate of 7.77%. This market focuses on providing therapeutic interventions, primarily antibiotics such as azithromycin and surgical procedures, to address infections caused by Chlamydia trachomatis and correct trichiasis. The industry is principally driven by the coordinated execution of the SAFE strategy and robust international drug donation programs that enable mass drug administration; indeed, the International Coalition for Trachoma Control reported that 44.4 million individuals received antibiotic treatment for trachoma in 2024.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 657.40 Million
Market Size 2031USD 1029.95 Million
CAGR 2026-20317.77%
Fastest Growing SegmentOral
Largest MarketNorth America

However, a major obstacle limiting market reach is the logistical complexity of distributing treatments to remote and conflict-affected regions. In these high-prevalence areas, infrastructure deficits and regional instability frequently disrupt medical supply chains and impede the deployment of surgical teams, effectively stalling efforts to achieve complete disease eradication.

Market Driver

The coordinated implementation of the WHO SAFE strategy acts as the primary catalyst for market advancement as nations accelerate efforts to meet 2030 elimination targets. This comprehensive framework, which combines surgery, antibiotics, facial cleanliness, and environmental improvement, mandates extensive interventions in endemic zones and fuels the demand for surgical consumables and therapeutic antibiotics, while governments prioritize validation processes through rigorous testing to confirm sustained low prevalence. The success of these structured efforts is evident, as the World Health Organization's 'Trachoma' fact sheet from October 2024 confirms that 20 countries have been validated for eliminating trachoma as a public health problem.

Strategic corporate drug donations and persistent funding from international non-governmental organizations further underpin market stability by ensuring a reliable supply of azithromycin and operational resources. These initiatives are essential for maintaining mass drug administration schedules in low-income regions where government budgets are often insufficient for procurement, with public-private partnerships effectively bridging the gap between clinical needs and commercial affordability. The scale of this support is highlighted by Pfizer's '2023 Impact Report' from March 2024, which noted the donation of the company's 1 billionth dose of Zithromax to the International Trachoma Initiative, a vital contribution given that the World Health Organization reported approximately 103 million people still lived in areas requiring trachoma interventions in 2024.

Market Challenge

The logistical difficulty of transporting treatments to remote and conflict-affected regions directly restricts the growth of the Global Trachoma Treatment Market by severing the critical link between supply and patient demand. Because the market relies fundamentally on Mass Drug Administration (MDA) campaigns and mobile surgical camps, any disruption to physical access immediately halts service delivery, while infrastructure deficits and safety concerns in unstable regions prevent the deployment of medical personnel and antibiotics. These barriers effectively reduce the actionable market size, rendering available therapeutic resources unusable in the areas where they are most urgently needed.

Consequently, this operational bottleneck leaves a vast segment of the at-risk population untreated, stalling progress despite the availability of donated medications. The magnitude of this inaccessibility prevents the market from closing the gap between potential demand and actual provision, a situation underscored by the World Health Organization's finding that, as of April 2025, approximately 102.6 million people resided in trachoma-endemic areas requiring interventions. This statistic emphasizes that a massive portion of the market remains logistically out of reach, preventing the complete execution of elimination strategies.

Market Trends

The adoption of smartphone-based digital diagnostic tools is fundamentally reshaping the Global Trachoma Treatment Market by modernizing the identification and tracking of active infection clusters. As traditional paper-based surveys prove inefficient for real-time decision-making, market stakeholders are integrating mobile health applications that utilize algorithm-based grading and GPS tagging to map prevalence with high precision, allowing for the rapid deployment of antibiotic regimens to micro-hotspots. The scale of this operational modernization is illustrated by Sightsavers' 'Annual Report 2024' from July 2025, which details 9.9 million eye examinations, a volume of service delivery increasingly enabled by digital platforms that streamline patient tracking and reporting in remote areas.

Simultaneously, the market is undergoing a transition to post-validation surveillance and monitoring strategies as more nations suppress active transmission below the threshold of public health concern. This trend necessitates a pivot from large-scale Mass Drug Administration (MDA) campaigns to targeted surveillance protocols designed to detect and rapidly respond to disease recrudescence, driving demand for specialized diagnostic training and sustainable monitoring frameworks rather than bulk antibiotic procurement. Highlighting the urgency of this transitional phase, the International Coalition for Trachoma Control's '2025 ICTC Gaps Analysis Report' from April 2025 notes that five countries have newly achieved prevalence targets for elimination, signaling a critical market shift toward funding and equipping robust pre-validation surveillance systems to secure these gains.

Key Market Players

  • Novartis AG
  • Gilead Sciences Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • BioCryst Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Boehringer Ingelheim GmBH
  • Pfizer, Inc.
  • Sanofi A.G.
  • Janssen Pharmaceutical, Inc.

Report Scope

In this report, the Global Trachoma Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Trachoma Treatment Market, By Route of Administration

  • Oral
  • Topical

Trachoma Treatment Market, By Drug Class

  • Macrolides
  • Tetracycline
  • Ophthalmic Anti-infective

Trachoma Treatment Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Trachoma Treatment Market.

Available Customizations:

Global Trachoma Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Trachoma Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Route of Administration (Oral, Topical)
    • 5.2.2. By Drug Class (Macrolides, Tetracycline, Ophthalmic Anti-infective)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Trachoma Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Route of Administration
    • 6.2.2. By Drug Class
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Trachoma Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Route of Administration
        • 6.3.1.2.2. By Drug Class
    • 6.3.2. Canada Trachoma Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Route of Administration
        • 6.3.2.2.2. By Drug Class
    • 6.3.3. Mexico Trachoma Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Route of Administration
        • 6.3.3.2.2. By Drug Class

7. Europe Trachoma Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Route of Administration
    • 7.2.2. By Drug Class
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Trachoma Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Route of Administration
        • 7.3.1.2.2. By Drug Class
    • 7.3.2. France Trachoma Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Route of Administration
        • 7.3.2.2.2. By Drug Class
    • 7.3.3. United Kingdom Trachoma Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Route of Administration
        • 7.3.3.2.2. By Drug Class
    • 7.3.4. Italy Trachoma Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Route of Administration
        • 7.3.4.2.2. By Drug Class
    • 7.3.5. Spain Trachoma Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Route of Administration
        • 7.3.5.2.2. By Drug Class

8. Asia Pacific Trachoma Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Route of Administration
    • 8.2.2. By Drug Class
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Trachoma Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Route of Administration
        • 8.3.1.2.2. By Drug Class
    • 8.3.2. India Trachoma Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Route of Administration
        • 8.3.2.2.2. By Drug Class
    • 8.3.3. Japan Trachoma Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Route of Administration
        • 8.3.3.2.2. By Drug Class
    • 8.3.4. South Korea Trachoma Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Route of Administration
        • 8.3.4.2.2. By Drug Class
    • 8.3.5. Australia Trachoma Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Route of Administration
        • 8.3.5.2.2. By Drug Class

9. Middle East & Africa Trachoma Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Route of Administration
    • 9.2.2. By Drug Class
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Trachoma Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Route of Administration
        • 9.3.1.2.2. By Drug Class
    • 9.3.2. UAE Trachoma Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Route of Administration
        • 9.3.2.2.2. By Drug Class
    • 9.3.3. South Africa Trachoma Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Route of Administration
        • 9.3.3.2.2. By Drug Class

10. South America Trachoma Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Route of Administration
    • 10.2.2. By Drug Class
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Trachoma Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Route of Administration
        • 10.3.1.2.2. By Drug Class
    • 10.3.2. Colombia Trachoma Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Route of Administration
        • 10.3.2.2.2. By Drug Class
    • 10.3.3. Argentina Trachoma Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Route of Administration
        • 10.3.3.2.2. By Drug Class

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Trachoma Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Novartis AG
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Gilead Sciences Inc.
  • 15.3. F. Hoffmann-La Roche Ltd.
  • 15.4. GlaxoSmithKline PLC
  • 15.5. BioCryst Pharmaceuticals, Inc.
  • 15.6. Merck & Co., Inc.
  • 15.7. Boehringer Ingelheim GmBH
  • 15.8. Pfizer, Inc.
  • 15.9. Sanofi A.G.
  • 15.10. Janssen Pharmaceutical, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer